The Apollo database project aims to advance patient care quality and outcomes by making kidney disease care more personalized and precise. It provides a view into the clinical care provided to more than 540,000 dialysis patients. Fresenius Medical Care says it’s the largest multinational, longitudinal database of its kind.
Phase one of the Apollo database project harmonizes data from the company’s global clinical systems into the cloud. It aggregates data from 40 countries across six continents on more than 350 patient treatment parameters. The AI-powered project includes information on more than 140 million dialysis treatments and more than 34 million laboratory assessments.
“Artificial intelligence is only as good as the data that powers it,” said Dr. Frank Maddux, global chief medical officer and member of the management board. “The Apollo database is not only helping advance our understanding of kidney disease and dialysis therapies through data-driven insights. It also provides data that is high quality, relevant and timely, three vital data attributes that are crucial to achieving AI aspirations at scale.”
More about the Fresenius Medical Care Apollo database
The database provides full anonymization of data and a streamlined pathway for global analytics. It stays adherent to the complex set of global, regional and local privacy requirements, including HIPAA and GDPR.
Stuart McGuigan, global chief information officer, called the data created “one of the company’s greatest competitive advantages.” McGuigan added that reimagining Fresenius’ digital infrastructure remains “a key part” of the company’s organizational transformation.
“The achievement of the Apollo Database project is an important benchmark in not just our digital transformation, but in our long-term AI strategy,” he said.
Len Usvyat, head of clinical advanced analytics, added that the scarcity of multinational datasets led to the initiative.
“This important data tool increases the speed and robustness of the company’s analytical capabilities and provides greater consistency in generating data-driven clinical insights,” Usvyat said. “The knowledge gained from these efforts have the potential to improve not just the practice of medicine, but more importantly the quality of life for people with kidney disease.”
